These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 26290064)

  • 1. Topiramate augmentation in a patient with obsessive-compulsive disorder.
    Van Ameringen M; Patterson B
    J Psychiatry Neurosci; 2015 Sep; 40(5):E31-2. PubMed ID: 26290064
    [No Abstract]   [Full Text] [Related]  

  • 2. Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder.
    Hollander E; Dell'Osso B
    Int Clin Psychopharmacol; 2006 May; 21(3):189-91. PubMed ID: 16528143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series.
    Van Ameringen M; Mancini C; Patterson B; Bennett M
    Depress Anxiety; 2006; 23(1):1-5. PubMed ID: 16178009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topiramate related obsessive-compulsive disorder.
    Ozkara C; Ozmen M; Erdogan A; Yalug I
    Eur Psychiatry; 2005 Jan; 20(1):78-9. PubMed ID: 15642451
    [No Abstract]   [Full Text] [Related]  

  • 5. [Obsessive-compulsive disorders in general practice. How the obsessive-compulsive neurotic is revealed by skin and hair].
    Kordon A; Broocks A; Hohagen F
    MMW Fortschr Med; 2003 May; 145 Suppl 2():4-7. PubMed ID: 14579475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder.
    Berlin HA; Koran LM; Jenike MA; Shapira NA; Chaplin W; Pallanti S; Hollander E
    J Clin Psychiatry; 2011 May; 72(5):716-21. PubMed ID: 20816027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of childhood obsessive-compulsive disorder with citalopram.
    Maud C; Stein DJ
    S Afr Med J; 1996 Jun; 86(6 Suppl):746, 748. PubMed ID: 9180769
    [No Abstract]   [Full Text] [Related]  

  • 8. Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors.
    Maina G; Albert U; Salvi V; Bogetto F
    J Clin Psychiatry; 2004 Oct; 65(10):1365-71. PubMed ID: 15491240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topiramate as an adjuvant treatment for obsessive compulsive symptoms in patients with bipolar disorder: a randomized double blind placebo controlled clinical trial.
    Sahraian A; Bigdeli M; Ghanizadeh A; Akhondzadeh S
    J Affect Disord; 2014 Sep; 166():201-5. PubMed ID: 25012432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Topiramate augmentation in treatment-resistant obsessive-compulsive disorder].
    Vinkers DJ; van der Wee NJ
    Tijdschr Psychiatr; 2008; 50(11):747-50. PubMed ID: 18991236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sertraline and obsessive compulsive disorder: new indication. Limited assessment.
    Prescrire Int; 2000 Aug; 9(48):112-3. PubMed ID: 11067720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose escitalopram treatment in patients with obsessive-compulsive disorder: a naturalistic case series.
    Shim GS; Kang DH; Kwon JS
    J Clin Psychopharmacol; 2008 Feb; 28(1):108-10. PubMed ID: 18204356
    [No Abstract]   [Full Text] [Related]  

  • 13. Association of paroxetine with suicide attempt in obsessive-compulsive disorder.
    Göder R; Friege L; Treskov V; Grohmann R; Aldenhoff JB
    Pharmacopsychiatry; 2000 May; 33(3):116-7. PubMed ID: 10855464
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of the selective serotonin reuptake inhibitor citalopram in a possible animal analogue of obsessive-compulsive disorder.
    Stein DJ; Mendelsohn I; Potocnik F; Van Kradenberg J; Wessels C
    Depress Anxiety; 1998; 8(1):39-42. PubMed ID: 9750979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbamazepine for serotonin reuptake inhibitor nonresponder case of obsessive compulsive disorder.
    Aggarwal A; Jain M; Garg A; Jiloha RC
    Indian J Med Sci; 2009 Oct; 63(10):468-9. PubMed ID: 19901487
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study.
    Mundo E; Bianchi L; Bellodi L
    J Clin Psychopharmacol; 1997 Aug; 17(4):267-71. PubMed ID: 9241005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram.
    Mullins CD; Shaya FT; Meng F; Wang J; Harrison D
    Pharmacotherapy; 2005 May; 25(5):660-7. PubMed ID: 15899727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impulse control disorders in frontotemporal dementia: spectrum of symptoms and response to treatment.
    Pompanin S; Jelcic N; Cecchin D; Cagnin A
    Gen Hosp Psychiatry; 2014; 36(6):760.e5-7. PubMed ID: 25042130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychogenic itch responding to topiramate.
    Calabrò RS; Bramanti P; Digangi G; Mondello S; Italiano D
    Psychosomatics; 2013; 54(3):297-300. PubMed ID: 23274005
    [No Abstract]   [Full Text] [Related]  

  • 20. Beyond depression: citalopram for obsessive-compulsive disorder.
    Pato MT
    Int Clin Psychopharmacol; 1999 May; 14 Suppl 2():S19-26. PubMed ID: 10471169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.